Clinical Trial Update: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 open-label, single-arm trial evaluating autologous M-CENK adoptive cell therapy with IL-15 superagonist N-803 in combination with gemcitabine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Gemcitabine (Gemzar) (gemcitabine)
• M-CENK adoptive cell therapy (M-CENK adoptive cell therapy)
• N-803

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Platinum-resistant Ovarian Cancer | Phase 2 | Status: RECRUITING